GlassScriptPhysician profile
Mohamed Hammami
NPI 1285049726
$565.35
in general payments reported to CMS, 2019-2025
9 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $47.15 · 2021: $248 · 2022: $66.61 · 2023: $73.37 · 2024: $21.11 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $203.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205.86 | 2021-2025 | Caplyta |
| Medtronic, INC. | $135.34 | 2021-2025 | Venaseal |
| Bioxcel Therapeutics, INC. | $50.88 | 2023 | Igalmi |
| Janssen Pharmaceuticals, INC | $47.15 | 2020 | |
| Neurocrine Biosciences, INC. | $44.66 | 2022 | |
| Braeburn INC. | $22.49 | 2023 | Brixadi |
| Alkermes, INC. | $21.95 | 2022 | |
| Glaxosmithkline, LLC. | $21.11 | 2024 | Trelegy Ellipta, Arexvy |
| Ultragenyx Pharmaceutical INC. | $15.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Hammami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.